Related Experiment Videos
[Prolactinoma in the male]
Zeitschrift Fur Die Gesamte Innere Medizin Und Ihre Grenzgebiete
|October 1, 1986
Summary
This study on male macroprolactinoma patients found surgery alone often fails to normalize prolactin levels and has a high recurrence rate. Dopamine agonist therapy is frequently needed post-operation.
Area of Science:
- Neuroendocrinology
- Neurosurgery
- Oncology
Background:
- Macroprolactinomas, large pituitary tumors secreting prolactin, can cause significant hormonal and visual disturbances.
- Male patients often present with symptoms like visual impairment, hypogonadism, and decreased libido.
Purpose of the Study:
- To evaluate clinical, endocrinological, and diagnostic findings in male macroprolactinoma patients.
- To assess the effectiveness of surgical treatment and the necessity of additional therapies.
Main Methods:
- Retrospective analysis of medical records from 13 male patients with macroprolactinomas.
- Data collected included anamnestic, clinical, endocrinological, and imaging findings.
- Treatment outcomes, including prolactin normalization and recurrence rates, were reviewed.
Main Results:
- Ophthalmological complaints and hypogonadism were the primary clinical manifestations.
- Diagnosis involved elevated serum prolactin, ophthalmological exams, and various imaging techniques.
- Exclusive surgical treatment resulted in a high rate of recurrence and failed to normalize prolactin levels in most cases.
Conclusions:
- Surgical intervention for macroprolactinomas in males often requires supplementary medical therapy with dopamine agonists.
- The decision to use bromocriptine as a primary treatment should be individualized based on patient factors.